LIVE Programme
CET Time
15:40-15:50 Yes – Felicitas Thol (Hannover)
Audience Voting
15:55-16:15 Panel discussion
16:15-17:15 SATELLITE SYMPOSIUM:
Title: Exploring the Immune and Inflammatory Microenvironments in the Search for New Therapies
Chair: Uwe Platzbecker (Leipzig)
Speakers: Raphael Itzykson (Paris), Uwe Platzbecker (Leipzig) & David Valcárcel (Barcelona)
This symposium is organized by NOVARTIS
17:20-17:50 Coffee Break
SESSION V – Specific Subtypes of MDS, based on Morphology and Molecular Biology
Chairs: Michaela Fontenay (Paris) & Eric Solary (Villejuif)
17:55-18:00 Introduction Michaela Fontenay (Paris)
Eric Solary (Villejuif)
18:00-18:15 MDS with Ring sideroblasts Michaela Fontenay (Paris)
18:15-18:30 CMML and other MDS/MPNs Eric Solary (Villejuif)
18:30-18:45. MDS with del 5q Ari Giagounidis (Düsseldorf)
18:45-19:00 Childhood MDS Charlotte Niemeyer (Freiburg)
SHORT COMMUNICATION:
19:00-19:10 IMPACT of RAS-Pathway Activation on Phenotype and Outcome Klaus Geissler (Vienna)
in Patients with Chronic Myelomonocytic Leukemia and a
TET2/SRSF2 Comutation
19:10-19:40 Panel discussion
Saturday, January 30, 2021
S
ESSION VI – Treatment of MDS
Chairs: Eva Hellström-Lindberg (Stockholm) & Raphael Itzykson (Paris)
13:30-13:35 Introduction Eva Hellström-Lindberg (Stockholm)
Raphael Itzykson (Paris)
13:35-13:50 Overview of MDS treatment Eva Hellström-Lindberg (Stockholm)
4
SCIENTIFIC PROGRAMME
SESSION I
ETIOLOGY OF MDS
SESSION II
BIOLOGY OF MDS –
GENETIC ABNORMALITIES
SESSION III
BIOLOGY OF MDS:
STEM CELLS AND THE
MICROENVIRONMENT
SESSION IV
DIAGNOSTIC WORKUP
AND PROGNOSTIC
FACTORS IN MDS
SESSION V
SPECIFIC SUBTYPES
OF MDS, BASED ON
MORPHOLOGY AND
MOLECULAR BIOLOGY
SESSION VI
TREATMENT OF MDS
SESSION VII
CURRENT PROGRESS IN
THE TREATMENT OF MDS
SESSION VIII
FUTURE TREATMENTS
AND TREATMENT
STRATEGIES IN MDS
SESSION IX
LATE-BREAKING TALKS
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
AS E-POSTERS
DISCLOSURES